Pulmonx Corp
Research Pulmonx Corp (LUNG) on Bullrun: market cap USD 107.37M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLUNG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 107.37M
- Financial periodQ2 2026
- RevenueUSD 22.76M
- Net income-USD 10.08M
- Free cash flow-USD 5.22M
- Gross margin78.0%
Valuation Snapshot
latest market cap is USD 107.37M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 90.50M | -USD 54.00M | -USD 32.83M | 74.2% | -1.33 | USD 69.75M | USD 37.10M | USD 54.12M |
| FY2024 | USD 83.79M | -USD 56.39M | -USD 32.98M | 74.0% | -1.44 | USD 70.91M | USD 37.18M | USD 85.81M |
| FY2023 | USD 68.68M | -USD 60.84M | -USD 38.42M | 73.9% | -1.6 | USD 83.55M | USD 37.24M | USD 118.32M |
| FY2022 | USD 53.66M | -USD 58.92M | -USD 46.40M | 74.3% | -1.59 | USD 101.74M | USD 17.32M | USD 154.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 107.37M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 92.10M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 270.15M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 488.43M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 315.36M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.18B | n/a | n/a | n/a |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pulmonx Corp's market cap?
Pulmonx Corp's market capitalization is USD 107.37M.
What does Pulmonx Corp do?
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.